Primary aldosteronism and obstructive sleep apnea: What do we know thus far?

Loh, Huai Heng; Sukor, Norlela

doi:10.3389/fendo.2022.976979

Cited by 5 publications

(4 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathophysiology of OSA has been associated with alterations in the reninangiotensin-aldosterone system. [79] Studies in animal models suggest that intermittent hypoxia and acute hypercapnia, as observed in OSA, are linked to elevated plasma aldosterone, independently of plasma renin activity. [80] Nonetheless, whether these changes contributed 7 This article is protected by copyright.…”

Section: Reported Prevalence Of Overt Pa In Patients With Osamentioning

confidence: 99%

Primary Aldosteronism Prevalence – An Unfolding Story

Charoensri

Turcu

2023

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Primary aldosteronism (PA) is characterized by dysregulated, renin-independent aldosterone excess. Long perceived as rare, PA has emerged as one of the most common causes of secondary hypertension. Failure to recognize and treat PA results in cardiovascular and renal complications, through processes mediated by both direct target-tissue insults, and indirectly, by hypertension. PA spans a continuum of dysregulated aldosterone secretion, which is typically recognized in late stages, after treatment-resistant hypertension and cardiovascular and/or renal complications develop. Determining the precise disease burden remains challenging, due to heterogeneity in testing, arbitrary thresholds, and populations studied. In this review, we summarize the reports on PA prevalence among the general population and in specific high-risk subgroups, highlighting the impact of rigid versus permissive criteria on PA prevalence perception.

show abstract

Section: Reported Prevalence Of Overt Pa In Patients With Osamentioning

confidence: 99%

Primary Aldosteronism Prevalence – An Unfolding Story

Charoensri

Turcu

2023

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…Hyperaldosteronism effect in fluid retention in the body [19]. Aldosterone excess leads to salt and water retention resulting in parapharyngeal edema and worsening the OSA condition [39]. Besides that, hypoxia induces endothelial dysfunction causing decrease the production of NO (nitric oxide).…”

Section: Mechanisms Of Diseasementioning

confidence: 99%

OSA and Resistant Hypertension: A Literature Review

Arini Indah Syahputri,

Rahmatul Islamiyah,

Susetyo Pikir

2023

IJRP

View full text Add to dashboard Cite

Resistant hypertension is a serious condition in which blood pressure remains uncontrolled despite using three or more antihypertensive medications in different classes. Resistant hypertension can lead to chronic kidney disease and cardiovascular diseases. One of the main causes of resistant hypertension is OSA. Based on research study, prevalence of OSA in resistant hypertension patients up to 83%. After reviewing previous research articles, it was found that there is an association between OSA and resistant hypertension.

show abstract

“…These effects encompass organ fibrosis, 3 cardiovascular diseases, 4 osteoporosis, 5 metabolic syndrome, new-onset diabetes mellitus, 6 anxiety, 7 and obstructive sleep apnea. 8 The prevalence rate varies from 3.9% in stage 1 hypertension 9 to 22% in patients with resistant hypertension. 10 Accurate diagnosis and timely treatment of primary hyperaldosteronism not only cure this form of secondary hypertension but also reduce associated end-organ damage.…”

Section: Introductionmentioning

confidence: 99%

“… 10 Accurate diagnosis and timely treatment of primary hyperaldosteronism not only cure this form of secondary hypertension but also reduce associated end-organ damage. 8 , 11 , 12 However, the real-world screening rate for primary hyperaldosteronism is low 13 and forms a major limitation to effective treatments of the disease. Surgical adrenalectomy is the recommended treatment for lateralized primary hyperaldosteronism.…”

Section: Introductionmentioning

confidence: 99%

Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis

Ho,

Hsiao,

et al. 2024

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: The effectiveness and side effects between different medical treatments in patients with primary hyperaldosteronism have not been systematically studied. Objective: To analyze the efficacy between different mineralocorticoid receptor antagonists (MRAs) and epithelial sodium channel (ENaC) inhibitors in a network meta-analysis (NMA) framework, while also evaluating adverse events. Design: Systematic review and NMA. Data sources and methods: The systematic review and NMA was reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, MEDLINE, the Cochrane library, and Excerpta Medica database (EMBASE) were searched for randomized controlled trials (RCTs) involving adult patients with primary hyperaldosteronism until 23 June 2023. Studies that compared the efficacy and side effects of different medical treatments of primary hyperaldosteronism were included. The primary outcomes included the effect on blood pressure, serum potassium, and major adverse cardiovascular events. The secondary outcomes were adverse events related to MRAs (hyperkalemia and gynecomastia). Frequentist NMA and pairwise meta-analysis were conducted. Results: A total of 5 RCTs comprising 392 participants were included. Eplerenone, esaxerenone, and amiloride were compared to spironolactone and demonstrated comparable effect on the reduction of systolic blood pressure. In comparison to spironolactone, eplerenone exhibited a less pronounced effect on reducing diastolic blood pressure [−4.63 mmHg; 95% confidence interval (CI): −8.87 to −0.40 mmHg] and correcting serum potassium (−0.2 mg/dL; 95% CI: −0.37 to −0.03 mg/dL). Spironolactone presented a higher risk of gynecomastia compared with eplerenone (relative risk: 4.69; 95% CI: 3.58–6.14). Conclusion: The present NMA indicated that the blood pressure reduction and potassium-correcting effects of the three MRAs may demonstrate marginal differences, with confidence levels in the evidence being very low. Therefore, further research is needed to explore the efficacy of these MRAs, especially regarding their impact on mortality and cardiovascular outcomes. Trial registration: PROSPERO (CRD: 42023446811).

show abstract

Primary aldosteronism and obstructive sleep apnea: What do we know thus far?

Cited by 5 publications

References 70 publications

Primary Aldosteronism Prevalence – An Unfolding Story

Primary Aldosteronism Prevalence – An Unfolding Story

OSA and Resistant Hypertension: A Literature Review

Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis

Contact Info

Product

Resources

About